Assetmark Inc. Buys 65,796 Shares of Sanofi $SNY

Assetmark Inc. boosted its stake in shares of Sanofi (NASDAQ:SNY) by 14.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 509,464 shares of the company’s stock after buying an additional 65,796 shares during the quarter. Assetmark Inc.’s holdings in Sanofi were worth $24,546,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new stake in shares of Sanofi during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its holdings in shares of Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares during the last quarter. Leonteq Securities AG grew its stake in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after buying an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of Sanofi in the third quarter valued at $29,000. Finally, Palisade Asset Management LLC acquired a new position in Sanofi during the third quarter worth $30,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Trading Up 1.0%

Shares of Sanofi stock opened at $44.66 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The firm has a 50-day moving average of $43.35 and a 200-day moving average of $45.52. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The stock has a market cap of $108.27 billion, a PE ratio of 12.47, a PEG ratio of 1.14 and a beta of 0.34.

Analyst Ratings Changes

A number of analysts have commented on SNY shares. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Wall Street Zen lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. Finally, BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.